Breaking Boundaries in Cancer Treatment: Siren Biotechnology Secures $28M to Launch Universal AAV Immuno-Gene Therapy

Siren Biotechnology, a trailblazer in the fight against cancer, is excited to announce that it has successfully raised $28,000,000 in its latest funding round. This significant investment underscores the confidence of investors in Siren’s groundbreaking approach and the potential of its Universal AAV Immuno-Gene Therapy. At Siren, the belief is clear: the fight against cancer needs new, big, bold ideas, and the company is fully committed to delivering on that promise by combining two transformative therapeutic technologies—AAV gene therapy and cytokine immunotherapy—into one powerful, reimagined modality. This funding will be strategically deployed to accelerate preclinical and clinical research, optimize delivery systems, and expand manufacturing capabilities to meet future demand. Furthermore, the new capital is set to bolster collaborations with leading research institutions and accelerate the development of advanced protocols that not only target tumor cells directly but also stimulate robust anti-tumor immunity. By integrating these two cutting-edge technologies, Siren is poised to overcome the critical challenges that have traditionally hindered progress in cancer treatment. The infusion of funds marks a pivotal milestone in the company’s ongoing mission to redefine cancer care and provide hope to patients who desperately need innovative therapeutic options. As the company moves forward, Siren Biotechnology remains steadfast in its commitment to innovation, excellence, and the relentless pursuit of solutions that have the potential to transform the landscape of cancer treatment, ultimately improving outcomes and saving lives.